محاضرة حول الحجامة وقوانينها الصحيحة التي بينها العلامة الإنساني محمد أمين شيخو من خلال الأحاديث النبوية الشريفة، وفوائدها الباهرة، وتأثيرها على الجسم.
وبيان لرأي الفريق الطبي السوري حول الحجامة.
مرجع تذكرة الدوائي الموقع لم يقبل نشر كامل الكتاب بسبب الحجم لتحميل الكتاب كاملاً
للجوال pdf
https://drive.google.com/open?id=0B3_wH3q91qxAZ1p2dzRqM0tkWlE
للكمبيوتر
https://drive.google.com/open?id=0B3_wH3q91qxAU1Q0YVl5SWhIblU
مايكروسوفت وورد word
https://drive.google.com/open?id=0B3_wH3q91qxAYUNzQmY5X05WY2s
Plasmapheresis is a medical procedure that separates blood components to remove plasma. There are three main types: autologous, therapeutic exchange, and donation. Autologous plasmapheresis removes a patient's own plasma, treats it, and returns it to remove antibodies, immune complexes, or toxins. It is used to treat various neurological, hematological, metabolic, dermatological, and renal diseases. Complications can include hypotension, allergic reactions, hemorrhage, hypocalcemia, and infections from replacement fluids. Plasmapheresis removes drugs and proteins from plasma like IVIG and monoclonal antibodies but not drugs like steroids that are widely distributed in tissues. It is used pre- and
immunomodulation either stimulation or suppression has a crucial role in clinical practice dealing with either malignancy or infection
organ transplantation also need
محاضرة حول الحجامة وقوانينها الصحيحة التي بينها العلامة الإنساني محمد أمين شيخو من خلال الأحاديث النبوية الشريفة، وفوائدها الباهرة، وتأثيرها على الجسم.
وبيان لرأي الفريق الطبي السوري حول الحجامة.
مرجع تذكرة الدوائي الموقع لم يقبل نشر كامل الكتاب بسبب الحجم لتحميل الكتاب كاملاً
للجوال pdf
https://drive.google.com/open?id=0B3_wH3q91qxAZ1p2dzRqM0tkWlE
للكمبيوتر
https://drive.google.com/open?id=0B3_wH3q91qxAU1Q0YVl5SWhIblU
مايكروسوفت وورد word
https://drive.google.com/open?id=0B3_wH3q91qxAYUNzQmY5X05WY2s
Plasmapheresis is a medical procedure that separates blood components to remove plasma. There are three main types: autologous, therapeutic exchange, and donation. Autologous plasmapheresis removes a patient's own plasma, treats it, and returns it to remove antibodies, immune complexes, or toxins. It is used to treat various neurological, hematological, metabolic, dermatological, and renal diseases. Complications can include hypotension, allergic reactions, hemorrhage, hypocalcemia, and infections from replacement fluids. Plasmapheresis removes drugs and proteins from plasma like IVIG and monoclonal antibodies but not drugs like steroids that are widely distributed in tissues. It is used pre- and
immunomodulation either stimulation or suppression has a crucial role in clinical practice dealing with either malignancy or infection
organ transplantation also need
THIS is a PowerPoint presentation denoting different clinical picture and case report of atypical prese tation
the question is: is it coindenance or autiological relation
New microsoft power point presentationdrsalwa22000
This document provides recommendations for fasting during Ramadan for those with diabetes. It categorizes risk levels as very high, high, moderate, and low based on factors like blood sugar control and medical history. For each risk level, it recommends whether fasting is advised against or can be done with/without caution. It also reviews common diabetes medications and provides guidance on any dosage adjustments or precautions needed when taking them during Ramadan fasting. Finally, it outlines the religious opinion of the Egyptian Fatwa Authority, which is that fasting should avoid hardship and harm for all patients with diabetes.
This document discusses various topics related to immunosuppressive drugs used in renal transplantation. It begins by reviewing mTOR inhibitors used in combination with calcineurin inhibitors, noting their synergistic effect. It then discusses a study finding lower rates of discontinuation and better graft function with mTORi-CNI compared to MMF/MPA-CNI. Finally, it briefly touches on induction immunosuppression methods, tolerance without immunosuppression, and withdrawal of steroids and calcineurin inhibitors.
This document discusses immunosuppressive therapy for renal transplantation. It covers various types of immunosuppressive drugs used for induction and maintenance, including calcineurin inhibitors (CNIs), mTOR inhibitors, steroids, and antiproliferatives. It provides information on monitoring drug levels, drug toxicities, and strategies to improve graft survival like avoiding high intrapatient drug level variability. It also addresses the impact of immunosuppressive drugs on male reproduction and pregnancy.
This document discusses post-transplant diabetes mellitus (PTDM), covering its definition, risk factors, diagnostic criteria, management, and the effects of various immunosuppressive and antidiabetic drugs. It provides questions and answers on topics like the most common cause of end-stage kidney disease in the US, risk factors for PTDM, criteria for diagnosing diabetes and prediabetes, preferred tests for diagnosing diabetes after transplantation, and factors that affect immunosuppressant and antidiabetic drug levels.
New microsoft office power point 97 2003 presentationdrsalwa22000
Membranoproliferative glomerulonephritis (MPGN) is characterized by three histopathologic findings: proliferation of mesangial and endothelial cells, thickening of peripheral capillary walls, and mesangial interposition into capillary walls. It can present with asymptomatic proteinuria and hematuria, nephrotic syndrome, acute nephritic syndrome, or recurrent gross hematuria. Treatment involves immunosuppression, antiplatelet agents, anticoagulants, and anti-inflammatory drugs. Recurrent disease is common after kidney transplantation.
New microsoft office power point 97 2003 presentationdrsalwa22000
Membranoproliferative Glomerulonephritis (MPGN) is a type of glomerular disease characterized by three histological findings: proliferation of mesangial and endothelial cells, thickening of capillary walls, and mesangial interposition into capillary walls. It accounts for 6-12% of renal biopsies performed to evaluate glomerular disease. Presentations include asymptomatic proteinuria and hematuria, nephrotic syndrome, acute nephritic syndrome, and recurrent gross hematuria. Recurrence is common after kidney transplantation.
This document discusses the role of continuous renal replacement therapy (CRRT) in liver transplantation. It provides details on how to prescribe CRRT, including blood flow, dose, mode, substitution fluid, dialysate flow, fluid removal, fluid addition, and anticoagulation. It compares CRRT to intermittent hemodialysis. It then presents a case scenario of a patient undergoing liver transplantation who develops hepatorenal syndrome and requires CRRT intraoperatively and postoperatively based on their condition of massive blood loss, hypotension, and anuria. The CRRT prescription and monitoring of the patient over one week is described, showing recovering kidney function.
This document discusses the role of continuous renal replacement therapy (CRRT) in liver transplantation. It provides details on how to prescribe CRRT, including blood and dialysate flow rates, substitution fluid used, and anticoagulation. It notes CRRT is useful for hemodynamically unstable patients undergoing liver transplant due to complications like blood loss and hypotension. The case scenario describes using CRRT intraoperatively and postoperatively for a patient with liver and kidney failure undergoing liver transplant who experienced blood loss and hypotension.
This document discusses sexual and reproductive health issues after kidney transplantation. It notes that more than half of male patients with renal failure have biochemical hypogonadism, which is a risk factor for sexual dysfunction. Several medications commonly used after transplantation can negatively impact erectile function and fertility in men. Treatment with phosphodiesterase 5 inhibitors can help erectile dysfunction. Female patients may experience ovulatory and menstrual irregularities due to hypothalamic-pituitary changes from chronic kidney disease. Pregnancy is possible after transplantation if kidney function is good with no proteinuria or hypertension and at least one year post-transplant. Fertility preservation techniques before transplantation like ovum pickup and preservation are discussed.
This document discusses living kidney donors for transplantation. It notes that living donation is beneficial as it provides superior graft survival and reduces waiting lists compared to deceased donation. Potential living donors are screened based on health criteria like being over 21, having normal kidney function, and no uncontrolled medical issues. While criteria have been expanded, donors must be carefully monitored long term to ensure no excess mortality or health issues result from donation.
During a 6-year period, 499 patients with morbid obesity and either end-stage renal disease or chronic kidney disease were evaluated for possible sleeve gastrectomy surgery. A total of 243 patients, 198 with end-stage renal disease and 45 with chronic kidney disease, underwent sleeve gastrectomy from December 2011 through February 2018. Immunosuppressive drugs, graft biopsy, and median follow-up period of 5.8 years were examined.
The document discusses hepatitis C virus (HCV) infection in patients with kidney disease. It covers several topics:
1) HCV is highly prevalent among patients undergoing dialysis, with rates ranging from 1.4-28.3% in developed countries and 4.7-41.9% in developing countries.
2) HCV can accelerate progression of chronic kidney disease and increase risk of end-stage renal disease. Successful treatment of HCV with antiviral therapy can improve kidney function and reduce dialysis risk.
3) Several direct-acting antiviral regimens, including paritaprevir/ritonavir/ombitasvir/dasabuvir, paritaprevir/
1) The document discusses using ultrasound measurement of the inferior vena cava (IVC) diameter to assess volume status in patients.
2) Measuring the IVC is a fast, reliable, and non-invasive method to detect volume status changes compared to other methods like central venous pressure measurement.
3) The document reviews the technique for measuring IVC diameter using ultrasound and interpreting the results to help guide clinical decisions like fluid administration in patients with abnormal volume status.
28. The ADVANCE trial
N Engl J Med 2008; 358:2560-2572
Mean HbA1c target 6.5%
Mean HbA1c target 7.3%
The ADVANCE trial randomly assigned 11,140 participants to study the effect of
intensive glucose control on major kidney outcomes in type 2 diabetes
Treatment effects on ESRD, need for RRT,, doubling of creatinine >200μmol/l, new-
onset macro or microalbuminuria, and progression or regression of albuminuria,
after a median of 5 years
ESRD by 65%
Microalbuminuria
by 9%,
Macroalbuminuria
by 30%.
30. ADA: <140/90
AACE: <130/80
Volume 52, Issue 4, December 2017, Pages 621-663
Include classes that reduce cardiovascular events
• (ACEI/ARB): First choice in diabetes with albuminuria
• Thiazide diuretics
• Dihydropyridine calcium channel blockers
• Consider bedtime dosing for at least 1 medication
Urinary albumin-creatinine ratio greater than 300 mg/g creatinine
• ACEI/ARB at maximum tolerated dose indicated for blood
pressure management
Blood pressure target
Review of 2017 Diabetes Standards of Care
ACEIs or ARBs are not recommended for :
• Patients Without hypertension
• Normal UACR less than 30